… to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare … scientific advisory board Dr. Yu’s research focuses on RNAediting and his expertise will help to develop the …
Development of Axiomer® RNA base editing technology platform continues across multiple therapeutic areas; initial pipeline targets to be disclosed in early 2023 with Analyst and Investor R&D event to be held in Q1 2023
Management Team appointments and p
Substantial progress in 2019 with final data from Phase 1/2 trial of sepofarsen for Leber’s congenital amaurosis 10 showing rapid, significant and durable improvements in vision; Phase 2/3 pivotal trial Illuminate initiated with data expected in H1 2021Phase 1/2 St
… to changing lives through the creation of transformative RNA therapies for severe genetic rare diseases, today … and ProQR’s RNA oligonucleotide platform and Axiomer RNAediting approaches. Event Details Date/Time: June 22, …